<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="1" ids="29864">Mannitol</z:chebi> therapy to treat <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> induces osmotic <z:mp ids='MP_0001762'>diuresis</z:mp> and electrolyte loss </plain></SENT>
<SENT sid="1" pm="."><plain>In neurocritical care patients, <z:chebi fb="120" ids="26216">potassium</z:chebi> is the electrolyte that most often needs replacement </plain></SENT>
<SENT sid="2" pm="."><plain>Objective of this study was to evaluate the effects of adding <z:chebi fb="120" ids="26216">potassium</z:chebi> sparing <z:chebi fb="40" ids="35498">diuretic</z:chebi> (canrenone) to <z:chebi fb="1" ids="29864">mannitol</z:chebi> therapy on <z:chebi fb="120" ids="26216">potassium</z:chebi> urinary excretion, <z:chebi fb="120" ids="26216">potassium</z:chebi> plasma levels, and incidence of new <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> in patients receiving neurocritical care for <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Fifty-six patients were prospectively assigned to <z:chebi fb="1" ids="29864">mannitol</z:chebi> or <z:chebi fb="1" ids="29864">mannitol</z:chebi> plus i.v. canrenone </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="120" ids="26216">Potassium</z:chebi> urinary excretion, <z:chebi fb="120" ids="26216">potassium</z:chebi> plasma levels, urinary volume, and the incidence of new <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> were recorded during the first 8 days of therapy </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: In patients treated with <z:chebi fb="1" ids="29864">mannitol</z:chebi> the <z:chebi fb="120" ids="26216">potassium</z:chebi> urinary excretion was stable over the first 3 days and significantly increased, compared to baseline, on day 4th to 8th (baseline 20.3 ± 10.6 mEq/l/die, day 8th 24.6 ± 10.6 mEq/l/die, P &lt; 0.05); while <z:chebi fb="120" ids="26216">potassium</z:chebi> plasma levels significantly decreased </plain></SENT>
<SENT sid="6" pm="."><plain>In patients receiving <z:chebi fb="1" ids="29864">mannitol</z:chebi> plus canrenone <z:chebi fb="120" ids="26216">potassium</z:chebi> urinary excretion decreased from day 3rd to 8th (baseline 21.9 ± 11.6 mEq/l/die, day 8th 15.9 ± 10.9 mEq/l/die, P &lt; 0.015) and <z:chebi fb="120" ids="26216">potassium</z:chebi> plasma levels increased but remained within <z:mpath ids='MPATH_458'>normal</z:mpath> values range </plain></SENT>
<SENT sid="7" pm="."><plain>The incidence of new <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> was higher in the <z:chebi fb="1" ids="29864">mannitol</z:chebi> group than the <z:chebi fb="1" ids="29864">mannitol</z:chebi> plus canrenone group (35.7 vs. 10.7%; P &lt; 0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>Urinary volumes, <z:chebi fb="120" ids="26216">potassium</z:chebi> balance, and <z:chebi fb="199" ids="26708">sodium</z:chebi> plasma concentration were similar in the 2 study groups </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: In patients receiving neurocritical care for <z:hpo ids='HP_0002181'>cerebral edema</z:hpo>, the adjunct of a <z:chebi fb="120" ids="26216">potassium</z:chebi> sparing <z:chebi fb="40" ids="35498">diuretic</z:chebi> (canrenone) to <z:chebi fb="1" ids="29864">mannitol</z:chebi> therapy reduces <z:chebi fb="120" ids="26216">potassium</z:chebi> urinary loss, prevents <z:hpo ids='HP_0002900'>hypokalemia</z:hpo>, and reduces the incidence of new <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> </plain></SENT>
</text></document>